Clinical trials
Locally Advanced Malignant Solid Neoplasm clinical trials
Below are recruiting locally advanced malignant solid neoplasm clinical trials, each written for real people, not researchers. We’re tracking 77 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07137416RecruitingPhase 1
Combination drug study for HER2-positive breast and other cancers
This study tests a new combination of two anti-cancer drugs (CX-5461 and T-DXd) for people with HER2-positive breast cancer or other solid tumors. It aims to see if the combination is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT05430399RecruitingPhase 3
Utidelone vs docetaxel for HER2-negative breast cancer
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Guangzhou, GangdongAges 18 years+ - NCT07664397RecruitingPhase 1
Imaging study of a new tracer for cancer detection
This study tests a new imaging tracer called [89Zr]DFO-YS5 that may help detect certain cancers on a PET-CT scan. The goal is to see if this tracer is safe and works well for finding tumors, which could one day help doctors plan better treatments.
San Francisco, CaliforniaAges 18 years+ - NCT07660432RecruitingPhase 1
Testing SIM0689 for advanced solid tumors
This study tests a new drug called SIM0689 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective, and researchers will look at tumor samples to understand which patients might benefit most.
Fuzhou, FujianAges 18 years+ - NCT07631793RecruitingPhase 1
Experimental vaccine for advanced solid tumors
This trial tests an experimental vaccine called YKYY031 for people with advanced solid tumors that have stopped responding to standard treatments. The vaccine aims to help your immune system fight cancer cells that carry specific markers. It may be an option if you have certain genetic markers and tumor proteins.
Beijing, Beijing MunicipalityAges 18–75 - NCT05918445RecruitingPhase 1/Phase 2
PM8002 for advanced solid tumors that have stopped responding
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
BaojiAges 18–75 - NCT07563972RecruitingPhase 1
Immune Cell Injection for Advanced Solid Tumors
This trial tests a new treatment where immune cells (called macrophage exosomes) are injected directly into your tumor to help your body fight the cancer. It's designed for advanced cancers that have not responded to standard treatments.
Chengdu, SichuanAges 18–65 - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT06051760RecruitingPhase 1
NV-001 for advanced solid tumors after standard treatments
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07080242RecruitingPhase 1
Study of BL-M14D1 for small cell lung cancer and neuroendocrine tumors
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
Huntsville, AlabamaAges 18 years+ - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06364410RecruitingPhase 1
Testing a new drug combo for stomach and other solid tumors
This trial tests a combination of two drugs, trastuzumab deruxtecan and azenosertib, for people with stomach cancer or other solid tumors that have a specific protein called HER2. It aims to see if this combination can help when other treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT06120283RecruitingPhase 1
Study of BGB-43395 alone or with other drugs for advanced solid tumors
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
Denver, ColoradoAges 18 years+ - NCT06075524Recruiting
How PD-1 therapy affects immune cells in advanced cancers
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
Rochester, MinnesotaAges 18 years+ - NCT05944237RecruitingPhase 1/Phase 2
Early trial for advanced cancers using HTL0039732
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
CambridgeAges 18 years+ - NCT05865002RecruitingPhase 1
Safety and drug test for AUR107 in advanced cancers
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05705492RecruitingPhase 2
Olanzapine to help cancer-related weight and appetite loss
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
Portland, OregonAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+
Hear when a new Locally Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Locally Advanced Malignant Solid Neoplasm trials by city
Studies with a site in or near these metro areas.
Locally Advanced Malignant Solid Neoplasm trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for locally advanced malignant solid neoplasm?
- Yes. Clin2 currently lists 77 recruiting locally advanced malignant solid neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced malignant solid neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced malignant solid neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.